The main purpose of the study was to compare topoisomerase 2α (TOP2A) status in invasive breast carcinomas to the outcome of a therapy containing neoadjuvant treatment with anthracyclines (a combination chemotherapy treatment for breast cancer, namely AC [cyclophosphamide, doxorubicin]). To achieve these goals we created a method of evaluation with criteria based on two methods used in the present study (immunohistochemical [IHC] and fluorescence in situ hybridization [FISH]). The threshold for positive immunohistochemically evaluated status was set for all cases with: nuclear stain intensity score 3+ in 10% or more nuclei and nuclear stain intensity score 2+ in 50% or more nuclei. Our results suggest that TOP2A status may be used as a predictive factor for patient selection for protocols which include anthracyclines as one of the chemotherapeutics. Both methods, IHC and FISH, are suitable for implementation for diagnostic purposes, but IHC positive status measured according to the criteria presented above is the best predictor of longer disease-free survival (DFS) according to our study. Immunohistochemical also gave satisfactory results in all analyzed cases in comparison to only 60% of cases analyzed by FISH.
Introduction
In the era of targeted therapy there is a need to establish predictive factors which will allow treatment to be personalized. In breast carcinoma, according to the St Gallen recommendation, in each case the following markers should be tested: estrogen receptor (ER), progesterone receptor (PgR), HER2, as well as the proliferation index by Ki67 protein before systemic treatment is introduced [1] [2] [3] [4] [5] .
There are a number of potentially valuable predictive markers both for new therapeutic agents and for those known for decades such as anthracyclines. Topoisomerase 2α (TOP2A) for years has been considered a potential predictive factor for anthracycline-containing therapies, although the results are still inconclusive [6] [7] [8] [9] [10] [11] .
Topoisomerase 2α is a nuclear enzyme that changes the way the DNA is organized in nuclei. Therefore TOP2A is required in almost all processes involving changes and untangling of DNA. This enzyme is encoded by the TOP2A gene located in the 17q12-21 region. This region is also responsible for human epidermal growth factor receptor 2 (HER2). HER2 is one of the most frequently amplified genes in breast cancer. The exact mechanism of rearrangement of this region is not completely understood; however, some data suggest that even though high copy numbers of TOP2A and HER2 are common findings, these genes belong to separate amplicons. HER2 status has often been used to select patients for analysis of TOP2A alterations. Clinical relevance has usually been investigated in the context of HER2 overexpression or HER2 amplification. This is also the case in the present study. It is possible because at the time of treatment of patients from our study (2002) (2003) (2004) (2005) group, anti-HER2 therapy were given in Poland after dissemination of neoplastic disease. Both TOP2A amplifications and deletions were shown to confer an adverse prognosis but also a greater benefit from anthracycline-containing therapy. Many authors have suggested the possibility of guiding therapy based on TOP2A status [9, [12] [13] [14] [15] . However, a recent metaanalysis did not confirm the predictive value of TOP2A alterations [9] . Information on the predictive role of TOP2A status, and even the percentage of cases of breast carcinoma which are TOP2A positive, since more than a decade have been surprisingly incoherent, partly because of different diagnostic methods (immunohistochemistry -IHC, fluorescent in situ hybridization -FISH, other molecular biology methods) and different thresholds for positive status [10, [16] [17] [18] . On the other hand, particularly in recent years, treatment of breast carcinoma is almost always a combination of different chemotherapeutics, radiotherapy, and different surgical techniques (e.g.: mastectomy, breast-conserving therapy, sentinel lymph node procedure, lymphadenectomy) [19, 20] . Recently introduced intrinsic subtypes for breast carcinoma make constructing a homogeneous group for such a study almost impossible [1, 2] . The group of patients in the present study was selected mainly on the basis of the same neoadjuvant therapy which was introduced according to the stage of the disease.
The main purpose of the study was to compare TOP2A status in invasive breast carcinomas to outcome of a therapy containing neoadjuvant treatment with anthracyclines (a combination chemotherapy treatment for breast cancer, namely AC (cyclophosphamide, doxorubicin)), in analyzed cases. Because of the published information on a correlation between the status of HER2 and TOP2A with the outcome of the therapy, the study group was subdivided into two tiers: HER2 positive and HER2 negative. We also wanted to find out if there is any influence of these factors on outcome of the therapy.
To achieve these goals we wanted to create an easy method of evaluation with criteria based on two methods used in the present study (IHC and FISH). In that period in the Maria Sklodowska-Curie Cancer Center anti-HER2 therapy was given only to patients after recurrence. Therefore, in our group both HER2 positive and HER2 negative tumors were treated similarly in the time of follow-up. HER2 status was positive in 62 of the analyzed cases. In 88 cases HER2 status was negative. At least 5-year observation was available for the study. Evaluation of TOP2A was performed retrospectively. Finally 148 cases (60 HER2 positive cases, 88 HER2 negative cases) were analyzed due to lack of valuable tissue block material in two cases. We divided our cases according to HER2 status because of published information on the correlation of HER2 status and TOP2A status in invasive breast carcinoma (Tables I and II) .
Material and methods
A list of 150 consecutive patients with invasive breast carcinoma, stage III according to the AJCC/ UICC classification, treated with chemotherapy (AC), was prepared in the Breast Cancer Clinic of the Maria Sklodowska-Curie Cancer Center (Table II) . In all but two cases, paraffin blocs containing tumor tissue were selected for IHC and FISH evaluation of TOP2A status. Both methods were used in all 148 cases, but, due to technical reasons, FISH re- 
Immunohistochemical method
For TOP2A immunocytochemistry, 4 μm sections were deparaffinized in xylene for 30 min and rinsed in ethanol. Sections were then subjected to antigen retrieval by immersion in citrate buffer (pH 6.0) preheated to 99°C for 40 min. Endogenous peroxidase was blocked by incubation in 3% H 2 O 2 in methanol for 30 min, followed by rinsing in Tris-buffered saline containing Tween 20. Immunohistochemical staining was performed with the EnVision+ System Kit (DakoCytomation, Glostrup, Denmark). Afterwards, the sections were incubated overnight in a humidity chamber with a monoclonal primary antibody against TOP2A (DakoCytomation; dilution 1 : 100) followed by incubation for 30 min with a dextran polymer conjugated with horseradish peroxidase enzyme and with goat anti-rabbit antibody. The antigen-antibody immunoreaction was revealed with 3,3'-diaminobenzidine tetrahydrochloride as the chromogen, and the slides were counterstained with hematoxylin.
For analysis we implemented an original system of IHC scoring partially based on the literature and partially on comparison of both our IHC and FISH results. Both a semi-quantitative intensity four-tier system (0, 1+, 2+, 3+) (Figs. 1-3 ) and the percentage value of stained cells (nuclei) were taken into account for IHC evaluation of TOP2A in the present study [16, 17] . The threshold for positive status was set for all cases with:
• nuclear stain intensity score 3+ in 10% or more nuclei, • nuclear stain intensity score 2+ in 50% or more nuclei. The precise criteria of our original IHC scoring system which was designed for this study is presented in Table III .
FISH method
In the study the TOP2A gene was evaluated using Path Vysion Abbott probes according to the instructions of the producer. FISH results suitable for interpretation in the fluorescent microscope were obtained in 98 cases. In those cases it was possible to calculate the ratio R = TOP2A/CEP17 -both types of signals were acceptable for interpretation. In 26 cases the average number of gene TOP2A signals per nucleus were calculated only -CEP17 signals were unsatisfactory. We did not include those cases in the study group. The remaining 24 cases were classified as non-diagnostic for TOP2A evaluation because:
• there were no visible signals for the TOP2A gene, • too few carcinoma cells were found in material for objective evaluation. For FISH evaluation we selected a method similar to that published by Mano et al. [18] . Cases with a ratio of 1.5 or more were considered amplified. Ad- ditionally, cases with a ratio of 10 or more were considered as highly amplified (HA) (Figs. 4-6 ).
Results
The IHC method for TOP2A gave visually acceptable result in 100% (148) of cases. The FISH method gave a visually acceptable result in 60% (98) of cases. Cases in which results from both methods were available and were used for "calibration" of the IHC scoring system are presented in Table III . We selected cases with amplification and compared them with intensity and proportions of nucleus staining. The final correlation of TOP2A status and DFS in studied cases was counted for IHC and FISH results separately, but statistically significant data were obtained for the IHC method. The scoring system based on the IHC method allowed clinical analysis of 138 cases in comparison to 92 available by FISH.
Positive status of TOP2A was found in 35.7% of cases by FISH and 46.6% by IHC. In our material it was found that there is a strong positive correlation between amplification of TOP2A and IHC results with positive status defined as presented in Table III (87.4%). In the HER2 negative group we found 54.5% of cases with negative TOP2A status and 45.5% with positive TOP2A status. In the HER2 positive group we found 51.7% of cases with negative TOP2A status and 48.3% with positive TOP2A status.
Results of TOP2A status measured by both methods (IHC and FISH) are presented in Table IV and V. Results from TOP2A status obtained by IHC and FISH were compared with DFS in both HER2 positive and HER2 negative groups. Results for those groups are shown in Tables VI and VII for the FISH  method and Tables VIII and IX for the IHC method.  Table X presents statistical significance of obtained data (confidence interval CI 95%) for the whole study group and for subgroups (TOP2A status measured by FISH, TOP2A status measured by IHC, and for HER2 status according to clinical data). According to the statistical analysis TOP2A positive status measured by IHC and using the scoring system introduced for this study correlates with longer DFS regardless of HER2 status (p (log-rank) < 0.001; Fig. 7) . Statistical data are shown in detail in Table XI .
Discussion
Analyzing data from the literature on TOP2A status and its role as a predictive factor in invasive breast carcinoma is a confusing experience [18] [19] [20] [21] [22] [23] . Outcomes of results both at the level of evaluation of TOP2A as well as at the level of interpretation are extremely different [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . If biology of breast carcinoma is similar around the world, then methods of TOP2A evaluation, criteria of interpretation and selection of patients are responsible for the differences [34] [35] [36] [37] [38] [39] [40] [41] . We put emphasis on criteria of interpretation, and decided to create out own system of We found in our study that cases with positive TOP2A status measured by the IHC method for TOP2A protein presented a statistically significantly better response to therapy which included anthracyclines as one of the chemotherapeutics (AC program in our study) in neoadjuvant therapy measured by relapses (DFS). In our study, we had a possibility to evaluate TOP2A in breast cancer cells using two methods (IHC and FISH) in all cases.
Using IHC and FISH methods, we compared the percentage of stained cells, strength of nuclear stain, presence of co-expressed cytoplasmic and membranous stain, amplification of TOP2A gene and also response to anthracycline-containing chemotherapy from clinical data. As the result of analysis of obtained data, we set our own cutoff points. We assumed that the best correlation with genomic aberrations is when both the percentage and strength of the stain are taken into account. In our study, a cutoff point for positive TOP2A status evaluated by the IHC method is at least 10% of carcinoma cells with strong (3+) nuclear staining or at least 50% of carcinoma with intermediate (2+) nuclear staining. The presented criteria as defined above correlate with amplification (ratio ≥ 1.5) and response to anthracycline-based neoadjuvant therapy (measured by DFS).
For the IHC method different criteria of scoring and different thresholds of positivity found in the literature make it impossible to perform valuable comparison of results achieved in numerous publications [16] [17] [18] [19] [20] [21] . In the case of FISH, criteria of scoring are more objective -counting dots theoretically generates less interobserver variation than classifying strength of the stain in IHC, especially when measured without an image analyzing system [17] . Im- In our study we found a similar frequency of TOP2A amplifications in both HER2 negative and HER2 positive breast cancers, which challenges the common opinion that TOP2A alteration is mostly restricted to HER2 positive tumors. On the other hand, we have only locally advanced cases in our study group, which is overrepresented by histologically high grade tumors. This factor alone can influence the proportion of TOP2A positive and negative cases [22, 23] .
In our study immunohistochemically evaluated TOP2A status statistically significantly correlates with DFS during 5-year follow-up in breast carcinoma stage III patients treated with anthracyclines-containing chemotherapy. Also in all cases with high amplification of the TOP2A gene there was 5-year DFS. However, the small number of those cases in the studied group makes this observation statistically irrelevant. Inconclusive results on the role of TOP2A in breast carcinoma biology and therapy are partially due to numerous thresholds of positivity measured by immunohistochemical analysis [16] [17] [18] .
Analyzing methodical data, we believe that FISH should not be used in routine diagnostic circumstances, at least alone. In around 40% of cases the results are below the quality that allows calculation of the TOP2A/CEP17 ratio.
Our results suggest that TOP2A status may be used as a predictive factor for patient selection for protocols which include anthracyclines as one of the chemotherapeutics. Both methods are suitable for implementation for diagnostic purposes, but IHC status measured according to criteria presented in Table III is the best predictor of DFS according to our study. IHC also gave satisfactory results in all analyzed cases in comparison to only 60% of cases analyzed by FISH.
